Switch theme
Sign up to access all valuation multiples
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
2020
680
LTM Revenue $154M
LTM EBITDA n/a
-$153M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Immatics has a last 12-month revenue of $154M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Immatics achieved revenue of $156M and an EBITDA of $34.5M.
Immatics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Immatics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $54.0M | $156M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$88.9M | $34.5M | XXX | XXX | XXX |
| EBITDA Margin | -165% | 22% | XXX | XXX | XXX |
| Net Profit | $37.5M | -$97.0M | XXX | XXX | XXX |
| Net Margin | 69% | -62% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Immatics's stock price is $4.
Immatics has current market cap of $514M, and EV of -$153M.
See Immatics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$153M | $514M | XXX | XXX | XXX | XXX | $-0.26 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Immatics has market cap of $514M and EV of -$153M.
Immatics's trades at -1.1x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Immatics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Immatics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$153M | XXX | XXX | XXX |
| EV/Revenue | -1.0x | XXX | XXX | XXX |
| EV/EBITDA | -4.4x | XXX | XXX | XXX |
| P/E | 33.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpImmatics's NTM/LTM revenue growth is -41%
Immatics's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Immatics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Immatics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Immatics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 189% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -139% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -19% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 30% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 95% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 125% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Immatics acquired XXX companies to date.
Last acquisition by Immatics was XXXXXXXX, XXXXX XXXXX XXXXXX . Immatics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Immatics founded? | Immatics was founded in 2020. |
| Where is Immatics headquartered? | Immatics is headquartered in United States of America. |
| How many employees does Immatics have? | As of today, Immatics has 680 employees. |
| Who is the CEO of Immatics? | Immatics's CEO is Dr. Harpreet Singh, PhD. |
| Is Immatics publicy listed? | Yes, Immatics is a public company listed on NAS. |
| What is the stock symbol of Immatics? | Immatics trades under IMTX ticker. |
| When did Immatics go public? | Immatics went public in 2020. |
| Who are competitors of Immatics? | Similar companies to Immatics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Immatics? | Immatics's current market cap is $514M |
| What is the current revenue of Immatics? | Immatics's last 12-month revenue is $154M. |
| What is the current EV/Revenue multiple of Immatics? | Current revenue multiple of Immatics is -1.1x. |
| What is the current revenue growth of Immatics? | Immatics revenue growth between 2023 and 2024 was 189%. |
| Is Immatics profitable? | Yes, Immatics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
